Evaluating the Clinical Efficacy of an Early-Stage Lung Cancer Detector

This is a randomized blinded clinical study.

Blood will be collected from patients onto a K2-EDTA tube (10-15 mL) then processed to separate the plasma. The plasma will be sent to the CPC lab for analysis of concentration levels for 21 biomarkers and results will be processed by the CPC proprietary algorithm. Results will be reflected as a positive or negative for lung cancer. The result will not be released to the primary doctor or patient.

The CPC001 diagnostic test is a blood serum test for the detection of NSCLC, which accounts for 85% of all lung cancers diagnosed in the U.S. CPC001 uses a multi-biomarker approach to identify associations between genes, proteins and diseases.